Does the media favor MBX or ZVRA?

In the previous week, MBX Biosciences had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 5 mentions for MBX Biosciences and 1 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.42 beat MBX Biosciences' score of 0.24 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GPCR or ZVRA?

In the previous week, Structure Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Zevra Therapeutics. Structure Therapeutics' average media sentiment score of 0.45 beat Zevra Therapeutics' score of 0.42 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, HCM or ZVRA?

HUTCHMED has higher revenue and earnings than Zevra Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $549.12M 4.51 $456.91M N/A N/A Zevra Therapeutics $106.47M 5.57 $83.23M $0.92 10.86

Does the media prefer HCM or ZVRA?

In the previous week, HUTCHMED had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for HUTCHMED and 1 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.42 beat HUTCHMED's score of 0.33 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HRMY or ZVRA?

In the previous week, Harmony Biosciences had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 6 mentions for Harmony Biosciences and 1 mentions for Zevra Therapeutics. Harmony Biosciences' average media sentiment score of 0.86 beat Zevra Therapeutics' score of 0.42 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zevra Therapeutics (ZVRA) Competitors

$9.99 -0.19 (-1.87%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$10.00 +0.01 (+0.09%)

As of 10/2/2026 07:55 PM Eastern

Compare

ZVRA vs. MBX, SUPN, GPCR, HCM, and HRMY

Should you buy Zevra Therapeutics stock or one of its competitors? Zevra Therapeutics's main competitors and comparable companies include MBX Biosciences (MBX), Supernus Pharmaceuticals (SUPN), Structure Therapeutics (GPCR), HUTCHMED (HCM), and Harmony Biosciences (HRMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zevra Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

35.0% of Zevra Therapeutics shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Zevra Therapeutics has a net margin of 42.82% compared to MBX Biosciences' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Zevra Therapeutics	42.82%	54.54%	34.15%

MBX Biosciences presently has a consensus target price of $83.89, indicating a potential upside of 43.38%. Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 171.70%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, MBX Biosciences had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 5 mentions for MBX Biosciences and 1 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.42 beat MBX Biosciences' score of 0.24 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Zevra Therapeutics	$106.47M	5.57	$83.23M	$0.92	10.86

Summary

Zevra Therapeutics beats MBX Biosciences on 12 of the 15 factors compared between the two stocks.

How does Zevra Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

35.0% of Zevra Therapeutics shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 42.82% compared to Supernus Pharmaceuticals' net margin of -13.23%. Zevra Therapeutics' return on equity of 54.54% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Zevra Therapeutics	42.82%	54.54%	34.15%

In the previous week, Zevra Therapeutics had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 1 mentions for Zevra Therapeutics and 0 mentions for Supernus Pharmaceuticals. Zevra Therapeutics' average media sentiment score of 0.42 beat Supernus Pharmaceuticals' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Neutral
Zevra Therapeutics	Neutral

Zevra Therapeutics has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.43	-$38.55M	-$1.92	N/A
Zevra Therapeutics	$106.47M	5.57	$83.23M	$0.92	10.86

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 48.26%. Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 171.70%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Supernus Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Summary

Zevra Therapeutics beats Supernus Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Structure Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zevra Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Zevra Therapeutics	$106.47M	5.57	$83.23M	$0.92	10.86

Zevra Therapeutics has a net margin of 42.82% compared to Structure Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Zevra Therapeutics	42.82%	54.54%	34.15%

Structure Therapeutics presently has a consensus price target of $110.91, suggesting a potential upside of 300.83%. Zevra Therapeutics has a consensus price target of $27.14, suggesting a potential upside of 171.70%. Given Structure Therapeutics' higher possible upside, equities research analysts clearly believe Structure Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Structure Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Zevra Therapeutics. Structure Therapeutics' average media sentiment score of 0.45 beat Zevra Therapeutics' score of 0.42 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zevra Therapeutics beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HUTCHMED presently has a consensus price target of $14.87, indicating a potential upside of 4.69%. Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 171.70%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Zevra Therapeutics has a net margin of 42.82% compared to HUTCHMED's net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Zevra Therapeutics	42.82%	54.54%	34.15%

HUTCHMED has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, HUTCHMED had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for HUTCHMED and 1 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.42 beat HUTCHMED's score of 0.33 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has higher revenue and earnings than Zevra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$549.12M	4.51	$456.91M	N/A	N/A
Zevra Therapeutics	$106.47M	5.57	$83.23M	$0.92	10.86

Summary

Zevra Therapeutics beats HUTCHMED on 11 of the 14 factors compared between the two stocks.

How does Zevra Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

In the previous week, Harmony Biosciences had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 6 mentions for Harmony Biosciences and 1 mentions for Zevra Therapeutics. Harmony Biosciences' average media sentiment score of 0.86 beat Zevra Therapeutics' score of 0.42 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.66	$158.69M	$3.08	12.87
Zevra Therapeutics	$106.47M	5.57	$83.23M	$0.92	10.86

Harmony Biosciences presently has a consensus target price of $47.44, indicating a potential upside of 19.69%. Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 171.70%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Harmony Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Zevra Therapeutics has a net margin of 42.82% compared to Harmony Biosciences' net margin of 18.88%. Zevra Therapeutics' return on equity of 54.54% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Zevra Therapeutics	42.82%	54.54%	34.15%

Summary

Harmony Biosciences beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$604.53M	$12.28B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.53%	16.77%
P/E Ratio	10.86	794.62	273.77	26.04
Price / Sales	5.57	790.44	619.77	92.59
Price / Cash	10.76	82.26	77.60	51.75
Price / Book	3.63	10.46	10.92	6.30
Net Income	$83.23M	$2.83B	$3.50B	$361.43M
7 Day Performance	-9.51%	-1.56%	-2.07%	-1.67%
1 Month Performance	-20.33%	-5.67%	-6.21%	-4.51%
1 Year Performance	2.46%	-4.72%	7.45%	2.03%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	4.3282 of 5 stars	$9.99 -1.9%	$27.14 +171.7%	+7.3%	$604.53M	$106.47M	10.86	61
MBX MBX Biosciences	2.6372 of 5 stars	$53.63 -3.2%	$77.00 +43.6%	+249.3%	$2.67B	N/A	N/A	63	Analyst Forecast Gap Up
SUPN Supernus Pharmaceuticals	3.5235 of 5 stars	$42.66 -1.5%	$62.83 +47.3%	-11.6%	$2.52B	$718.95M	N/A	778
GPCR Structure Therapeutics	2.1782 of 5 stars	$35.93 -0.2%	$110.91 +208.7%	+3.9%	$2.51B	N/A	N/A	281	Analyst Downgrade
HCM HUTCHMED	1.5606 of 5 stars	$13.94 +0.3%	$14.87 +6.6%	-11.9%	$2.43B	$548.51M	N/A	1,796

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. MBX, SUPN, GPCR, HCM, and HRMY

How does Zevra Therapeutics compare to MBX Biosciences?

Summary

How does Zevra Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Zevra Therapeutics compare to Structure Therapeutics?

Summary

How does Zevra Therapeutics compare to HUTCHMED?

Summary

How does Zevra Therapeutics compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. MBX, SUPN, GPCR, HCM, and HRMY

How does Zevra Therapeutics compare to MBX Biosciences?

Do insiders & institutionals believe in MBX or ZVRA?

Is MBX or ZVRA more profitable?

Do analysts recommend MBX or ZVRA?

Does the media favor MBX or ZVRA?

Which has more volatility & risk, MBX or ZVRA?

Which has preferable earnings and valuation, MBX or ZVRA?

Summary

How does Zevra Therapeutics compare to Supernus Pharmaceuticals?

Do insiders and institutionals believe in SUPN or ZVRA?

Is SUPN or ZVRA more profitable?

Does the media favor SUPN or ZVRA?

Which has stronger valuation and earnings, SUPN or ZVRA?

Do analysts prefer SUPN or ZVRA?

Which has more risk and volatility, SUPN or ZVRA?

Summary

How does Zevra Therapeutics compare to Structure Therapeutics?

Which has more volatility and risk, GPCR or ZVRA?

Do insiders and institutionals hold more shares of GPCR or ZVRA?

Which has better valuation & earnings, GPCR or ZVRA?

Is GPCR or ZVRA more profitable?

Do analysts prefer GPCR or ZVRA?

Does the media favor GPCR or ZVRA?

Summary

How does Zevra Therapeutics compare to HUTCHMED?

Do insiders & institutionals have more ownership in HCM or ZVRA?

Do analysts prefer HCM or ZVRA?

Is HCM or ZVRA more profitable?

Which has more volatility & risk, HCM or ZVRA?

Does the media prefer HCM or ZVRA?

Which has stronger earnings and valuation, HCM or ZVRA?

Summary

How does Zevra Therapeutics compare to Harmony Biosciences?

Does the media favor HRMY or ZVRA?

Do insiders and institutionals have more ownership in HRMY or ZVRA?

Which has higher valuation & earnings, HRMY or ZVRA?

Do analysts recommend HRMY or ZVRA?

Which has more risk & volatility, HRMY or ZVRA?

Is HRMY or ZVRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools